IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

prnewswire

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer – NEWSnet – News… as it used to be

More Press Releases

April 30, 2026

Syngenta Group Reports Q1 2026 Results

April 30, 2026

LatticeFlow AI Launches the First Public Registry of AI Frameworks Mapped to Ready-to-Run Evaluations

April 30, 2026

Avolon Q1 Net Income up 32% to US$191 Million

April 30, 2026

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

Syngenta Group Reports Q1 2026 Results

LatticeFlow AI Launches the First Public Registry of AI Frameworks Mapped to Ready-to-Run Evaluations

Avolon Q1 Net Income up 32% to US$191 Million

Omdia: Global Smartphone Shipments Exceed Expectations With 1% Growth in 1Q26, but Second-Half Outlook Remains Uncertain